Bruker : Q1 2021 Earnings Webcast

BRUKER CORPORATION (NASDAQ: BRKR)

Q1 2021 Earnings Presentation May 5, 2021

Frank H. Laukien, President & CEO

Gerald Herman, Executive Vice President & Chief Financial Officer

Miroslava Minkova, Senior Director of Investor Relations & Corporate Development

BRUKER CORPORATION

Safe Harbor Statement

Any statements contained in this presentation which do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our fiscal year 2021 financial outlook, including our outlook for revenue growth, non-GAAP operating margin, non-GAAP EPS and non-GAAP tax rate; management's expectations for future financial and operational performance, expected growth, and business outlook; statements regarding our business focus and expected market growth; the impact of COVID-19 on our business and our responses to the pandemic, including cost reduction initiatives; our portfolio transformation; share count; tax rate; and product performance. Any forward-looking statements contained herein are based on current expectations, but are subject to risks and uncertainties that could cause actual results to differ materially from those indicated, including, but not limited to, risks and uncertainties relating to the length and severity of the COVID-19 pandemic, the impact of the pandemic on global economic conditions and the length and severity of any resulting recession, the impact of any supply chain disruptions, continued volatility in the capital markets, the impact of Project Accelerate, the integration and assumption of liabilities of businesses we have acquired or may acquire in the future, fluctuations in foreign currency exchange rates and their impact, our ability to successfully implement our restructuring initiatives and other cost reduction initiatives, changing technologies, product development and market demand and acceptance of our products, the success of our R&D investment initiatives, the cost and pricing of our products, manufacturing, competition, loss of key personnel, dependence on collaborative partners, key suppliers and contract manufacturers, capital spending and government funding policies, changes in governmental regulations, the use and protection of intellectual property rights, litigation, and other risk factors discussed from time to time in our filings with the Securities and Exchange Commission, or SEC. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2020, as may be updated by our quarterly reports on Form 10-Q. We expressly disclaim any intent or obligation to update these forward-looking statements other than as required by law.

© 2021 Bruker	+	- confidential	Q1 2021 Earnings Presentation |	May 5, 2021	|	2
		-

Q1 2021

Business Update

3

Q1 2021 BUSINESS UPDATE

Q1 2021: Business and Market Recovery Lead to Significant Step Ups in Revenues, Margins and EPS

Q1 2021 Performance Year-over-Year

Q1 Financials

❖	Revenues increase $130.7M, or +30.8%	Revenues [$M]

• • Organic growth of +23.8%, with BSI up +25.6% and BEST up +7.1%
  • Acquisitions add +0.8%
  • Favorable FX translation of +6.2%
• Non-GAAPgross margin of 51.3%, up +460 bps
• Non-GAAPoperating margin of 18.4%, compared to 7.6% in Q1-20
• • Significant revenue growth, improved gross margin and OPEX leverage
• GAAP EPS of $0.37, compared to $0.07 in Q1-20
• Non-GAAPEPS of $0.44, compared to $0.14 in Q1-20

554.7	+30.8%
	424.0
Q1-21	Q1-20

Non-GAAP EPS

Q1-20+214.3%

Q1-21

Reconciliations of non-GAAP to GAAP financial measures are available in our earnings press release and at the end of this presentation. Y-o-y: year over year. Bps: basis points

© 2021 Bruker	+	- confidential	Q1 2021 Earnings Presentation |	May 5, 2021	|	4
		-

GROUP OVERVIEW

Q1 2021 Revenue Performance Year-over-Year(1)

Bruker BIOSPIN Group

• BIOSPIN grows >20%, as customer demand and instrument deliveries recover
• BIOSPIN systems revenue up strongly, including customer acceptance of two GHz-class systems
• Aftermarket and software revenues grow

Bruker CALID Group

• CALID grows >20%, with strong demand in life science mass spectrometry and molecular spectroscopy
• Continued robust growth in timsTOF 4D proteomics business, along with broader mass spec recovery
• Microbiology and molecular diagnostics higher, SARS-CoV-2 testing revenue ~$7M in Q1 2021, up year- over-year, but down sequentially from Q4 2020
• Molecular spectroscopy (FTIR/NIR/Raman) with strong growth amid recovering applied, industrial and academic markets

(1)All in constant currency, and in comparison to the three months ended March 31, 2020.

© 2021 Bruker	+	- confidential	Q1 2021 Earnings Presentation	|	May 5, 2021	|	5
		-